Loading clinical trials...

A Study of Lampalizumab Intravitreal Injections Administered Every Two Weeks or Every Four Weeks to Participants With Geographic Atrophy | Clinical Trials | Clareo Health

COMPLETEDPHASE2

A Study of Lampalizumab Intravitreal Injections Administered Every Two Weeks or Every Four Weeks to Participants With Geographic Atrophy

A Phase II, Multicenter, Randomized, Single-Masked, Sham Injection-Controlled Exposure-Response Study of Lampalizumab Intravitreal Injections Administered Every Two Weeks or Every Four Weeks to Patients With Geographic Atrophy

NCT02288559•Genentech, Inc.

View on ClinicalTrials.gov

Summary

This multicenter, randomized, single-masked, sham injection-controlled study will investigate the exposure-response and safety of lampalizumab administered intravitreally every 2 weeks (Q2W) or every 4 weeks (Q4W) for 24 weeks in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). A safety run-in assessment will be conducted prior to initiating enrollment in the randomized study.

Eligibility

Age

60 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Complement Factor I (CFI) profile biomarker-positive result
•Women of child bearing potential and men should remain abstinent or use contraceptive methods

Exclusion Criteria

•History of vitrectomy surgery, submacular surgery, or other surgical intervention for AMD in study eye
•Previous subfoveal focal laser photocoagulation in study eye
•Laser photocoagulation in the study eye
•Prior treatment with external-beam radiation therapy or transpupillary thermotherapy in study eye
•Previous intravitreal drug administration in study eye. A single intraoperative administration of a corticosteroid during cataract surgery at least 3 months prior to screening is permitted
•Previous cell-based intraocular treatment in study eye
•Intraocular surgery in study eye
•Uncontrolled glaucoma and history of glaucoma-filtering surgery in study eye
•History of corneal transplant in study eye
•GA in either eye due to causes other than AMD
+13 more criteria

Locations (36)

Barnet Dulaney Perkins Eye Center

Mesa, Arizona, United States

University of Arizona; Banner University Medical, Department of Opthalmology

Tucson, Arizona, United States

Northwest Arkansas Retina Associates

Springdale, Arkansas, United States

Retinal Diagnostic Center

Campbell, California, United States

The Retina Partners

Encino, California, United States

Loma Linda University

Loma Linda, California, United States

San Diego Retina Associates

Oceanside, California, United States

West Coast Retina Medical Group

San Francisco, California, United States

California Retina Consultants

Santa Barbara, California, United States

Colorado Retina Associates, PC

Golden, Colorado, United States

Key Dates

Start Date

March 30, 2015

Primary Completion Date

June 2, 2017

Completion Date

June 2, 2017

Last Updated

September 25, 2019

Enrollment

ACTUAL participants

Conditions

Geographic Atrophy

Interventions

Sham

OTHER

Lampalizumab

DRUG

A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy

NCT06779773

Geographic AtrophyMacular Degeneration

View study

RECRUITINGPHASE2

Phase 2 Study of ADX-038 in Participants With Geographic Atrophy

NCT06990269

Geographic Atrophy Secondary to Age-related Macular Degeneration

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 25, 2019Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study of Lampalizumab Intravitreal Injections Administered Every Two Weeks or Every Four Weeks to Participants With Geographic Atrophy

Inclusion Criteria

Exclusion Criteria

A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy

Phase 2 Study of ADX-038 in Participants With Geographic Atrophy

A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Macular Degeneration

Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

A Phase IIb Randomized, Multicenter Trial of Subretinal CPCB-RPE1 in Advanced Dry AMD (Geographic Atrophy)

Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy